Entering 2014, the foreign generic drug giants could not contain the commotion. On January 1, the global pharmaceutical giant Pfizer's commercial business formally separated and operated independently. At the same time, Paul Bizarro, CEO of Actavis, the world's third largest generic drug maker, announced that the company will completely withdraw from the Chinese market.
This series of news is interpreted by the industry as the global generic drug market will face major adjustments, and the local market share of Chinese generic drug companies is expected to increase. Among them, Hong Kong companies represented by Hengrui will face major development opportunities.
Facing the industry’s predictions, Hong Kong pharmaceutical companies have stated that the “retreat and survival” policy of foreign-funded generic pharmaceutical companies is expected to free up the market for their own development, but if they want to seize opportunities, the key is to rely on their own strength to speak.